سعر ريباثا 140مجم/مل قلم للحقن 2024

Repatha (evolocumab) 140 mg/mL solution for subcutaneous injection in single-dose prefilled pen(s), 1 pen(s) per pack; a fully human monoclonal antibody against PCSK9 marketed in Egypt by Amgen > Multipharma.

• Reduce risk of major adverse cardiovascular events in adults at increased riskPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet and exercise to reduce LDL-C in primary hypercholesterolemiaPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Heterozygous and homozygous familial hypercholesterolemiaPopulation: Adults and children aged 10 years and olderDailyMed (U.S. National Library of Medicine)

• Common (>5% and more than placebo) in hypercholesterolemia trials: nasopharyngitis, headache, oropharyngeal pain, influenza, upper respiratory tract infection; injection-site reactions also reported.International label, same product · DailyMed (U.S. National Library of Medicine)

• History of serious hypersensitivity reaction to evolocumab or any excipient.International label, same product · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity reactions including angioedema; discontinue and treat if serious reactions occur. Needle cover of some presentations contains latex.International label, same product · DailyMed (U.S. National Library of Medicine)

• Human data are insufficient to evaluate drug-associated risk; no effects on pregnancy or infant development in monkeys at up to 12 times the maximum human exposure.International label, same product · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk; consider benefits of breastfeeding with the mother's clinical need and potential effects on the infant.International label, same product · DailyMed (U.S. National Library of Medicine)

• Evolocumab: Binds PCSK9 and prevents it from targeting LDL receptors for degradation, increasing LDL receptor recycling and lowering circulating LDL-C.